The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. by Borazan, Ali et al.
BACKGROUND: Markers of an acute phase reaction,
such as C-reactive protein (CRP) or tumor necrosis
factor-alpha (TNF-a) and interleukin (IL)-6, are pre-
dictive for cardiovascular morbidity and mortality in
normal subjects and in chronic renal failure patients.
In this study, we aimed to investigate serum TNF-a, IL-
6, IL-10 and CRP levels in continuous ambulatory
peritoneal dialysis (CAPD) and hemodialysis (HD)
patients.
Materials and methods: Serum levels of TNF-a, IL-6,
IL-10 and CRP levels were measured in 30 patients
who were just diagnosed with end-stage renal failure
and treated, with 16 CAPD (nine female, seven male)
and 14 HD (eight female, six male) patients, before
CAPD or HD treatment and after 3 months from the
beginning of CAPD or HD in patients with no clinical
signs of infection. The control groups were 20
healthy persons of similar age and sex. Serum levels
of TNF-a, IL-6, IL-10 and CRP were measured by
enzyme-linked immunosorbent assay in stable CAPD
and HD patients and in healthy persons.
Results: The mean serum levels of TNF-a, IL-6, IL-10
and CRP showed no significant differences between
the CAPD and HD patients for the beginning values
and the third month of treatment. However, serum
TNF-a, IL-6, IL-10 and CRP levels were higher than the
control group in the CAPD and HD patients regarding
the beginning values and the third month of treat-
ment (p B /0.001).
Conclusions: CAPD and HD of the renal replacement
therapy have no effects on serum CRP and cytokines.
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Introduction
Cardiovascular diseases are the major reason for
mortality and morbidity of patients with chronic renal
failure (CRF).
1 The cardiovascular death rate in CRF
patients is predicted as 9% per year, being 10-fold to
20-fold higher than the normal population.
1,2 C-
reactive protein (CRP) is an acute-phase protein
whose synthesis in the liver is regulated by different
cytokines. Serum levels of CRP in the absence of
active disease are low, but can rise up to 1000-fold in
patients with an inflammatory reaction. Besides being
a marker of inflammation, CRP itself may have pro-
inflammatory properties since it can activate the
complement system.
3
The inflammatory response is orchestrated by
cytokines, especially tumor necrosis factor-alpha
(TNF-a) and interleukin (IL)-6. Both regulate the
production of acute-phase proteins, have potent
effects on lipid and carbohydrate metabolism, and
are linked with an increased risk of coronary artery
disease in subjects with normal renal function.
3,4 Pro-
inflammatory cytokines also regulate vascular adhe-
sion. TNF-a in particular promotes the expression of
soluble cell adhesion molecule (CAM) by endothelial
cells.
5 Furthermore, increased plasma levels of solu-
ble CAM have been reported in CRF patients.
6 Thus it
is possible that cytokines could drive the increased
levels of acute-phase proteins and soluble CAM
observed in patients at risk of coronary artery disease.
Most of these studies were based on single-point
measurements of CRP or IL-6 plasma levels, and
mortality during subsequent years was linked to the
initial value. This concept was chosen without any
knowledge of the time-dependent changes in these
markers even in the absence of an acute illness.
Therefore, we investigated the patterns of CRP and
some cytokines (TNF-a, IL-6, IL-10) in selected
groups of continuous ambulatory peritoneal dialysis
(CAPD) and hemodialysis (HD) patients.
Short Communication
ISSN 0962-9351 print/ISSN 1466-1861 online/04/30201-04 – 2004 Taylor & Francis Ltd
DOI: 10.1080/09511920410001713493
201Research design and methods
Patients
This study was carried out on 30 patients (17 female,
13 male) who were just diagnosed with end-stage
renal failure. Sixteen patients (nine female, seven
male) were treated with CAPD, and in 14 patients
(eight female, six male) HD was performed. The
control group consisted of 20 healthy persons (11
female, nine male) of similar age and sex. All
participants gave written consent. Clinically unstable
patients and those with tumors, inflammatory dis-
eases, or those treated with immunosuppressives
were excluded. No patient showed signs of inflam-
mation or infection during the study period.
Ambulatory HD patients were hemodialyzed on
hollow-fiber polysulfone membrane dialyzators with
a 1.2 m
2 surface area (Polysulfon UF 4.0; Hemoflow
F5, Fresenius, Germany) with bicarbonate-containing
solutions for 4 h three times weekly. Peritoneal
dialysis solutions of 2 l with 1.36%, and when
necessary 3.86%, glucose were used three or four
times a day by the patients using CAPD. All the
patients received a chronic renal failure diet consist-
ing of 35 kcal/kg, including 1.2/1.4 g/kg of protein,
1000/1500 mg of calcium, 700 mg of phosphorus
and 250 mg of magnesium, polyvitamins and recom-
binant human erythropoietin.
Cytokines and CRP assays
Blood samples for TNF-a, IL-6, IL-10 and CRP levels
were taken from the subjects in the morning after 12
h of fasting. Samples were stored at  /208C. Serum
levels of TNF-a, IL-6, IL-10 and CRP were determined
by enzyme-linked immunosorbent assay. Primary
and biotinylated antibodies against TNF-a, IL-6, IL-
10 were purchased from R&D Systems Europe
(Abingdon, UK). Primary and biotinylated antibodies
against CRP were purchased from Dako (Glostrup,
Denmark).
For TNF-a, IL-6, IL-10, the sensitivity ranged
between 2 and 3 pg/ml. For CRP, it was usually 1
ng/ml.
Statistical analysis
Statistical analysis was performed by the SPSS for
windows (version 10.0) statistical package (SPSS Inc.,
Chicago, IL, USA). All the numerical variables are
presented as mean9 /standard deviation. Because of
the abnormal distribution of the data, the means of
the two groups were compared with the Mann/
Whitney U-test. If more than two measurements
were performed, Kruskal/Wallis one-way variance
of analysis was used. If a significant level of pB /0.05
was found, the values were compared with Wilcoxon
signed-rank test. pB /0.05 was considered significant.
Results
The CAPD group consisted of 16 patients (nine
female, seven male) with a mean age of 41.69 /6.0
years (range, 17/64 years), whereas the HD group
consisted of 14 patients (eight female, six male) with
a mean age of 43.09 /8.0 years (range, 18/66 years),
and the healthy group consisted of 20 patients (11
female, nine male) with a mean age of 42.09 /9.0
(range, 26/55 years). Patient characteristics and
primary renal disease are presented in Table 1. There
was no significant difference between groups regard-
ing age and sex.
The means9 /standard deviations of serum levels
and statistical analysis results of CAPD, HD and
control groups, at baseline and after 3 months of
TNF-a, IL-6, IL-10 and CRP are presented in Table 2.
There were no differences between and within in the
serum TNF-a, IL-6, IL-10 and CRP level at baseline
and after 3 months in the CAPD and HD groups
(p  /0.05). However, in CAPD and HD patients the
serum TNF-a, IL-6, IL-10 and CRP levels were higher
than levels in the control group both at baseline and 3
months after treatment (pB /0.001). In the CAPD
patients no peritonitis episode along the study period
was observed.
Discussion
Chronic uremia is considered a pro-inflammatory
state associated with high cardiovascular morbidity
and mortality.
3 Serum IL-6 and TNF-a were increased
in CRF, particularly in dialyzed patients. Compared
with controls, IL-6 was elevated in dialysis patients,
and TNF-a was elevated in predialysis and dialyzed
CRF patients.
7 CRP levels were increased in CRF and
it is thought that this may be an independent risk
factor that may cause progressive
atherosclerosis.
2,810
Table 1. Subject characteristics and primary diseases of the
patients
CAPD
patients
HD
patients
Controls
Age (years) 419 /64 3 9 /84 2 9 /9
Gender (female/male) 9/7 8/6 11/9
Primary disease
Diabetic nephropathy 7 4
Chronic glomerulonephritis 5 2
Hypertensive nephropathy 2 1
Obstructive nephropathy 2 4
Polycystic renal disease / 2
Amyloidosis / 1
Total 16 14 20
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CRP levels were significantly increased in the subjects
who were treated with hemodialysis and peritoneal
dialysis.
9,10 In cases prior to dialysis, the levels of
serum CRP and acute phase protein were found to be
related with an increase in the intima-media surface
of the carotid artery, and other positive and negative
acute phase reactants such as albumin, fibrinogen
Apo A-1 and Lp. Serum amyloid A levels were
correlated with CRP and some of these proteins
may be an additional predictor and/or reasonable
factor considering high cardiovascular risk in both
HD and peritoneal dialysis patients.
2,3,8,9 In the
present study we found wide variability of CRP and
TNF-a, IL-6 and IL-10 even in stable CAPD and HD
patients without signs of infection. Serum TNF-a, IL-
6, IL-10 and CRP levels in the CAPD and HD patients
were higher than those in the control group at to the
beginning values and after 3 months of treatment.
However, there were no differences between and
within the serum TNF-a, IL-6, IL-10 and CRP levels at
baseline and after 3 months in CAPD and HD
patients.
CRP levels in the present study (averaging 2.0 mg/
dl) are higher than in some previous studies for stable
CRF patients without signs of infection. In the
literature a wide range of CRP levels in CRF patients
are reported. Docci et al. observed CRP levels of 7.4
mg/dl in dialysis patients,
9 and Zimmermann et al.
reported that the increase in the CRP levels was 46%
in hemodialysis patients.
10 Owen and Lowrie re-
ported that this increase was 35%.
11 The reason
why the ratio of the CRP increase is high in the
CAPD group is probably that the inflammation in the
CAPD patient can be exaggerated both by the
peritoneal irritation and the decrease in the removal
of the cytokines because of the decrease in the
residual renal functions.
12
Thus, it seems that an individual baseline CRP level
can be established for each patient and these levels
appear to be well distinguishable between subjects. If
these levels reflect the inflammatory state for each
individual, they may also predict the cardiovascular
risk, as reported for large populations.
13,14 However,
to establish these individual baseline levels, at least
three measurements of plasma levels of CRP in the
absence of an acute illness appear to be necessary.
Macy et al. reported inter-individual variation of
92.5% and intra-individual variation of 42.2% for
CRP plasma levels in 26 healthy blood donors over
a 6-month period,
15 compared with 88% and 51% in
the present study. Thus, the variation of CRP is similar
in normal subjects and HD patients, although the
mean CRP levels are much higher in HD patients (2
mg/dl versus 0.17 mg/dl). Assuming that a patient’s
baseline inflammation really predicts cardiovascular
risk, the ideal marker of this level should not be
shown, but it appears that for acute-phase proteins
multiple measurements are needed to assess cardio-
vascular risk in CRF patients.
In conclusion, we found that serum CRP and some
cytokine levels were higher in CAPD and HD patients
compared with control subjects. However, renal
replacement therapies have no effects on serum
CRP and cytokines levels within a 3-month period.
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